Celecoxib as adjunctive therapy in schizophrenia: A double-blind, randomized and placebo-controlled trial

Akhondzadeh, Shahin; Tabatabaee, Maryam; Amini, Homayoun; Abhari, S A Ahmadi; Abbasi, Seyed Hesamedin; Behnam, Behnaz

doi:10.1016/j.schres.2006.11.016

Cited by 267 publications

(167 citation statements)

References 24 publications

Supporting

Mentioning

152

Contrasting

Unclassified

Order By: Relevance

“…[9][10][11][12][13] All together, these studies suggest that COX-2 inhibitors could be developed as potential agents for the treatment of depression. [23][24][25][26][27] However, there is probably a spectrum of inflammation for patients with MDD and it would be useful to measure cytokines before and after treatment as a predictor and mediator of response to COX-2 inhibitors. [25,27] The limitations of this study, including the relatively small sample size and only a fixed dose of celecoxib, should be taken into account and this indicates the need for further research.…”

Section: Discussionmentioning

confidence: 99%

Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial

et al. 2009

View full text Add to dashboard Cite

Background: The pathophysiology of depression is associated with the hyperactivity of immune inflammatory responses. Cyclooxygenase-2 inhibitors such as celecoxib reduce the production of pro-inflammatory cytokines. The purpose of the present investigation was to assess the efficacy of celecoxib as an adjuvant agent in the treatment of major depression in a six-week double blind and placebo controlled trial. Methods: Forty adult outpatients who met the DSM-IV-TR criteria for major depression participated in the trial. Patients have a baseline Hamilton Rating Scale for Depression score of at least 18. Patients were allocated in a random fashion: 20 to fluoxetine 40 mg/day plus celecoxib 400 mg/day (200 mg bid) (morning and evening) and 20 to fluoxetine 40 mg/ day plus placebo. Patients were assessed by a psychiatrist at baseline and after 1, 2, 4, and 6 weeks after the medication started. Results: Although both protocols significantly decreased the score of Hamilton Rating Scale for Depression over the trial period, the combination of fluoxetine and celecoxib showed a significant superiority over fluoxetine alone in the treatment of symptoms of major depression. There were no significant differences in the two groups in terms of observed side effects. Conclusion: The results of this study suggest that celecoxib may be an effective adjuvant agent in the management of patients with major depression and anti-inflammatory therapies should be further investigated.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial

et al. 2009

View full text Add to dashboard Cite

show abstract

“…When translating these findings into clinical trials, initial studies have shown a positive effect of medication targeting the immune system when used as an add-on treatment to antipsychotics (4)(5)(6). To aid further development of this therapeutic approach, tools for directly assessing the status of the brain immune system are needed to allow for patient stratification and monitoring of treatment effects.…”

mentioning

confidence: 99%

Positron Emission Tomography Studies of the Glial Cell Marker Translocator Protein in Patients With Psychosis: A Meta-analysis Using Individual Participant Data

Plavén-Sigray

Matheson

Collste

et al. 2018

Biological Psychiatry

110

102

View full text Add to dashboard Cite

BACKGROUND: Accumulating evidence suggests that the immune system may be an important target for new treatment approaches in schizophrenia. Positron emission tomography and radioligands binding to the translocator protein (TSPO), which is expressed in glial cells in the brain including immune cells, represents a potential method for patient stratification and treatment monitoring. This study examined whether patients with first-episode psychosis and schizophrenia had altered TSPO levels compared with healthy control subjects. METHODS: PubMed was searched for studies comparing patients with psychosis with healthy control subjects using second-generation TSPO radioligands. The outcome measure was total distribution volume (V T ), an index of TSPO levels, in frontal cortex, temporal cortex, and hippocampus. Bayes factors (BFs) were applied to examine the relative support for higher, lower, or no difference in patients' TSPO levels compared with healthy control subjects. RESULTS: Five studies, with 75 participants with first-episode psychosis or schizophrenia and 77 healthy control subjects, were included. BFs showed strong support for lower V T in patients relative to no difference (all BFs .

show abstract

“…Osteoprotegerin expression is related to COX-2 activity, 52 and treatment with a COX-2 inhibitor has been shown to be an effective adjunctive treatment in schizophrenia. 53 However, at present, the relation between calcium homeostasis, COX-1, OPG and mental disorders is unknown. Taken together, OPG level appears to be a stable and reliable marker not only of bone homeostasis and vascular calcification but also of inflammation, potentially mirroring 2 interacting pathogenic processes in severe mental disorders.…”

Section: Discussionmentioning

confidence: 99%

Osteoprotegerin levels in patients with severe mental disorders

Hope

Melle²,

Aukrust³

et al. 2010

jpn

View full text Add to dashboard Cite

Background: Severe mental disorders are associated with elevated levels of inflammatory markers. In the present study, we investigated whether osteoprotegerin (OPG), a member of the tumour necrosis factor receptor family involved in calcification and inflammation, is elevated in patients with severe mental disorders. Methods: We measured the plasma levels of OPG in patients with severe mental disorders (n = 312; 125 with bipolar disorder and 187 with schizophrenia) and healthy volunteers (n = 239). Results: The mean plasma levels of OPG were significantly higher in patients than in controls (t 531 = 2.6, p = 0.01), with the same pattern in bipolar disorder and schizophrenia. The increase was significant after adjustment for possible confounding variables, including age, sex, ethnic background, alcohol consumption, liver and kidney function, diabetes, cardiovascular disease, autoimmune diseases and levels of cholesterol, glucose and C-reactive protein. Limitations: Owing to the cross-sectional design, it is difficult to determine causality. Conclusion: Our results indicate that elevated OPG levels are associated with severe mental disorders and suggest that mechanisms related to calcification and inflammation may play a role in disease development.

show abstract

Celecoxib as adjunctive therapy in schizophrenia: A double-blind, randomized and placebo-controlled trial

Cited by 267 publications

References 24 publications

Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial

Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial

Positron Emission Tomography Studies of the Glial Cell Marker Translocator Protein in Patients With Psychosis: A Meta-analysis Using Individual Participant Data

Osteoprotegerin levels in patients with severe mental disorders

Contact Info

Product

Resources

About